ASF1A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5779515	0.52	8/20
SCHEMBL5779517	0.52	8/20
SCHEMBL1669400	0.63	7/20
SCHEMBL1669403	0.63	7/20
SCHEMBL1669478	0.57	7/20
SCHEMBL3632266	0.57	7/20
SCHEMBL1669969	0.57	7/20
SCHEMBL1669976	0.57	7/20
SCHEMBL3634256	0.55	7/20
SCHEMBL3634262	0.55	7/20
SCHEMBL3629235	0.54	7/20
SCHEMBL3629238	0.54	7/20
SCHEMBL3633321	0.54	7/20
SCHEMBL3633326	0.54	7/20
SCHEMBL8298584	0.67	6/20
SCHEMBL1670101	0.62	6/20
SCHEMBL1670107	0.62	6/20
SCHEMBL1672435	0.61	6/20
SCHEMBL1672436	0.61	6/20
SCHEMBL8298592	0.60	6/20

Clinical trials — most relevant to ASF1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus	nan	ACTIVE_NOT_RECRUITING
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease	nan	COMPLETED
Impact of Metabolic Health on Sperm Epigenetic Marks in Humans	nan	ACTIVE_NOT_RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Genetics of Familial and Sporadic ALS	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ASF1A binder may also engage these)

Protein	Name	Similarity
Q2KIG1	—	1.000	Q2KIG1 →
Q3C1E9	—	1.000	Q3C1E9 →
Q9CQE6	—	1.000	Q9CQE6 →
Q69DB9	—	1.000	Q69DB9 →
Q6NYY4	—	1.000	Q6NYY4 →
Q9DAP7	—	0.999	Q9DAP7 →
Q17QJ0	—	0.999	Q17QJ0 →
Q4PBU8	—	0.998	Q4PBU8 →
Q9NVP2	—	0.997	Q9NVP2 →
Q7T0M6	—	0.997	Q7T0M6 →
Q54N45	—	0.996	Q54N45 →
Q6DIP1	—	0.996	Q6DIP1 →
PHKB	Phosphorylase kinase beta subunit	0.995	landscape →
Q9V464	—	0.995	Q9V464 →
P0CM26	—	0.994	P0CM26 →
Q44241	—	0.994	Q44241 →
Q66JA9	—	0.994	Q66JA9 →
Q02272	—	0.994	Q02272 →
Q6ZQV5	—	0.994	Q6ZQV5 →
G5EC37	—	0.993	G5EC37 →
P0CM27	—	0.993	P0CM27 →
Q9C9M6	—	0.993	Q9C9M6 →
Q6INE2	—	0.993	Q6INE2 →
Q6NY34	—	0.992	Q6NY34 →
P97588	—	0.992	P97588 →
Q8YSC1	—	0.992	Q8YSC1 →
Q9CQA8	—	0.992	Q9CQA8 →
Q6CN69	—	0.991	Q6CN69 →
P42003	—	0.991	P42003 →
Q39QA9	—	0.991	Q39QA9 →